NASDAQ:PTI Proteostasis Therapeutics (PTI) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free PTI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.41▼$0.5750-Day Range$1.00▼$22.4252-Week Range$0.87▼$2.72Volume139,453 shsAverage Volume1.04 million shsMarket Capitalization$27.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Proteostasis Therapeutics alerts: Email Address Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Proteostasis Therapeutics Stock (NASDAQ:PTI)Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.Read More Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> PTI Stock News HeadlinesJuly 20, 2023 | bizjournals.comGreensboro joins incentive offers for $55M Honda expansion at PTI; Guilford County up nextMarch 13, 2023 | bloomberg.comFederal Police Summons India Minister in Bribery Probe, PTI SaysMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.October 6, 2022 | nj.com7 years later, probation and PTI for pair in North Bergen low-show/no-show job schemeOctober 26, 2021 | finance.yahoo.comImplied Volatility Surging for Proteostasis Therapeutics (PTI) Stock OptionsSee More Headlines Receive PTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Proteostasis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/16/2020Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:PTI CUSIPN/A CIK1445283 Webwww.proteostasis.com Phone617-225-0096FaxN/AEmployees44Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,130,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-75.39% Return on Assets-55.04% Debt Debt-to-Equity RatioN/A Current Ratio6.69 Quick Ratio6.69 Sales & Book Value Annual Sales$5 million Price / Sales5.48 Cash FlowN/A Price / Cash FlowN/A Book Value$1.22 per share Price / Book0.43Miscellaneous Outstanding Shares52,185,000Free FloatN/AMarket Cap$27.41 million OptionableNot Optionable Beta1.16 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMs. Meenu Chhabra (Age 48)Pres, CEO & Director Comp: $844.78kDr. Marija Zecevic (Age 46)Chief Commercial Officer Comp: $530.46kMichael L. AlfieriHead of Fin.Dr. Benito Munoz (Age 58)Chief Scientific Officer Ms. Janet L. Smart Esq. (Age 63)Ph.D., J.D., Sr. VP of Legal Affairs Dr. Geoffrey S. Gilmartin (Age 52)Chief Medical Officer Ms. Claudia StyslingerInvestor Relations Exec.More ExecutivesKey CompetitorsSpruce BiosciencesNASDAQ:SPRBFSD PharmaNASDAQ:HUGESol-Gel TechnologiesNASDAQ:SLGLAlaunos TherapeuticsNASDAQ:TCRTOrgenesisNASDAQ:ORGSView All Competitors PTI Stock Analysis - Frequently Asked Questions How were Proteostasis Therapeutics' earnings last quarter? Proteostasis Therapeutics, Inc. (NASDAQ:PTI) released its quarterly earnings results on Monday, November, 16th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.01. What other stocks do shareholders of Proteostasis Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include Idera Pharmaceuticals (IDRA), BHP Group (BHP), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Amarin (AMRN), Matinas BioPharma (MTNB), Micron Technology (MU), Rite Aid (RAD), VBI Vaccines (VBIV) and Acasti Pharma (ACST). When did Proteostasis Therapeutics IPO? Proteostasis Therapeutics (PTI) raised $51 million in an initial public offering on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers. This page (NASDAQ:PTI) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteostasis Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.